The Modified Glasgow Prognostic Scores as a Predictor in Diffuse Large B Cell Lymphoma Treated with R-CHOP Regimen.
10.3349/ymj.2014.55.6.1568
- Author:
Yundeok KIM
1
;
Soo Jeong KIM
;
Dohyu HWANG
;
Jieun JANG
;
Shin Young HYUN
;
Yu Ri KIM
;
Jin Seok KIM
;
Yoo Hong MIN
;
June Won CHEONG
Author Information
1. Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea. Jwcheong70@yuhs.ac
- Publication Type:Original Article ; Evaluation Studies
- Keywords:
Modified Glasgow Prognostic Score;
diffuse large B cell lymphoma;
prognostic factor
- MeSH:
Adult;
Aged;
Antibodies, Monoclonal, Murine-Derived/therapeutic use;
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use;
C-Reactive Protein/*metabolism;
Cyclophosphamide/therapeutic use;
Doxorubicin/therapeutic use;
Female;
Glasgow Outcome Scale;
Humans;
Lymphoma, Large B-Cell, Diffuse/blood/*diagnosis/*drug therapy/mortality;
Male;
Middle Aged;
Multivariate Analysis;
Prednisone/therapeutic use;
Prognosis;
Remission Induction;
Retrospective Studies;
Serum Albumin/*metabolism;
Survival Rate;
Treatment Outcome;
Vincristine/therapeutic use
- From:Yonsei Medical Journal
2014;55(6):1568-1575
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: The modified Glasgow Prognostic Score (mGPS) consisting of serum C-reactive protein and albumin levels, shows significant prognostic value in several types of tumors. We evaluated the prognostic significance of mGPS in 285 patients with diffuse large B cell lymphoma (DLBCL), retrospectively. MATERIALS AND METHODS: According to mGPS classification, 204 patients (71.5%) had an mGPS of 0, 57 (20%) had an mGPS of 1, and 24 (8.5%) had an mGPS of 2. RESULTS: Our study found that high mGPS were associated with poor prognostic factors including older age, extranodal involvement, advanced disease stage, unfavorable International Prognostic Index scores, and the presence of B symptoms. The complete response (CR) rate after 3 cycles of R-CHOP chemotherapy was higher in patients with mGPS of 0 (53.8%) compared to those with mGPS of 1 (33.3%) or 2 (25.0%) (p=0.001). Patients with mGPS of 0 had significantly better overall survival (OS) than those with mGPS=1 and those with mGPS=2 (p=0.036). Multivariate analyses revealed that the GPS score was a prognostic factor for the CR rate of 3 cycle R-CHOP therapy (p=0.044) as well as OS (p=0.037). CONCLUSION: mGPS can be considered a potential prognostic factor that may predict early responses to R-CHOP therapy in DLBCL patients.
